Evidence map›Paper›PMID 41726884›Full record

ArticlebioRxiv : the preprint server for biology2026

A Framework for Comparing Mouse Neoantigen Immunogenicity.

Peter J Matulich, Carly N Sprague, Victoria P Schuster, Alyssa M Granados, Rohan B Chaudhari, Megan L Burger

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Peter J MatulichDepartment of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
Carly N SpragueDepartment of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
Victoria P SchusterDepartment of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
Alyssa M GranadosDepartment of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
Rohan B ChaudhariDepartment of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
Megan L BurgerDepartment of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Grace B Gill · 1997 to 2026
$60.5M
NCI NIH HHS P30 CA069533
6 · The paper itself

Abstract

Cytotoxic CD8+ T cell responses targeting tumor neoantigens are critical for immunotherapy efficacy and are widely studied across different preclinical mouse tumor models. Defined neoantigens are commonly introduced to enable tracking of tumor-specific T cells; however, variation in neoantigen choice may yield immune phenotypes attributable to differences in neoantigen immunogenicity, complicating interpretation of tumor-intrinsic mechanisms. Here, we determined the relative immunogenicity of a set of 25 commonly used mouse tumor-derived and model neoantigens to facilitate comparison of neoantigens across studies. We found that

Indexed as

antigen strengthimmunotherapyNeoantigenpeptide-MHC stabilitypreclinical tumor models

Identifiers

PMID41726884
PMCPMC12918814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.